FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMENT AT 1-800-710-4674

Phase 1 REFMAL 381 (Phase 1 open at BAM only) A Phase 1, Open-Label, Multicenter, Safety Study of (BMS- Phase I 936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Therapeutic Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Nivolumab and abraxane provided Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

REFMAL-404: TGR-1202-102 (pending) A Phase I Study Evaluating the Safety and Efficacy of TGR-1202 Alone and Phase I in Combination with either nab-paclitaxel + Gemcitabine or with FOLFOX in Therapeutic Patients with Select Relapsed or Refractory Solid Tumors. TGR-1202 provided

HEMATOLOGY HEMREF-31: TGR-1202-101 (phase 1 open at A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR- KWD only) 1202 in Patients with Relapsed or Refractory Hematologic Malignancies Phase I Therapeutic TGR-1202 provided

MM-56: CFZ013 (phase 1 open at KWD only) Phase 1b Study of Carfilzomib Administered Once Weekly in Combination Phase Ib with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma Therapeutic Carfilzomib provided

BMT-10: INCB 039110-108 (pending 4th qtr) A Randomized, Parallel-Cohort Phase I Study of INCB039110 in Phase I Combination with Corticosteriods for the Treatment of Grade II-IV Acute Therapeutic Graft-Versus-Host Disease INCB039110 provided

METASTATIC, REFRACTORY, HER2+, BREAST BRE-200 (Phase 1 open at BAM only) A Phase II Study with Lead-In Safety Cohort of Cabazitaxel plus Lapatinib as Phase II Therapy for HER2-Positive Metastatic Breast Cancer Patients with Therapeutic Intracranial Metastases Cabazitaxel/Lapatinib provided Page 1 of 17 September 1, 2015

Molecular Profiling PRO-02: ML28897 MY PATHWAY: An Open-Label Phase IIA Study Evaluating / Phase IIA , Erlotinib, Vemurafenib, and Vismodegib in Patients who Have Therapeutic Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Trastuzumab, Pertuzumab, Erlotinib, Predictive of Response to One of These Agents Vemurafenib, Vismodegib provided

PRO-11: CBGJ398XUS04 Modular phase II study to link targeted therapy to patients with pathway Phase II activated tumors: Module 6 – BGJ398 for patients with tumors with FGFR Therapeutic genetic alterations BGJ398 provided

PRO-12: CLDK378AUS23 (pending) Modular phase II study to link targeted therapy to patients with pathway Phase II activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors Therapeutic have aberrations in ALK or ROS1 Ceritinib provided

Bladder Clinical Trials SECOND-LINE GU-122: WO29637 (pending 3rd Qtr) A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Phase III Antibody) in Combination with versus Sunitinib in Patients Therapeutic with Untreated Advanced Renal Cell Carcinoma MPDL3280A, bevacizumab, sunitinib provided

GU-123: WO2935 (pending) A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Phase Ib/II MPDL3280A Administered with or without Bacille Calmette-Guerin in Therapeutic Patients with High-Risk Non-Muscle-Invasive Bladder Cancer MPDL3280A provided

Page 2 of 17 September 1, 2015

GU-126: ACE-ST-005 (pending 3rd Qtr) Randomized Phase 2 Trial of ACP-196 and Immunotherapy Phase II Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Therapeutic Carcinoma (RAPID CHECK study) ACP-196 provided

Breast Clinical Trials NEOADJUVANT, TNBC BRE-238: M14-011 A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Phase III Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Therapeutic Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Veliparib/Carboplatin provided Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)

FIRST-LINE, ADVANCED, HR+ BRE-252: LEE011E2301 A Phase III randomized, double-blind, placebo-controlled study of LEE011 Phase III or placebo in combination with tamoxifen and goserelin or a non-steroidal Therapeutic aromatase inhibitor (NSAI) and goserelin for the treatment of LEE011/placebo provided premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer

SECOND- OR THIRD-LINE, ADVANCED, HR- BRE-266: GO29689 (pending 4th Qtr) A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant Phase II in Postmenopausal Women with Advanced or Metastatic ER+/HER2- Breast Therapeutic Cancer Resistant to Aromatase Inhibitor Therapy GDC-0810 provided

METASTATIC, FIRST-LINE, TNBC BRE-231: CDX011-04 A Randomized Multicenter Phase II Study of CDX-011 (CR011-vcMMAE) in Phase II Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Therapeutic Cancer CDX-011 provided

BRE-242: INCB 18424-268 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Phase II Combination with Capecitabine in Subjects With Advanced or Metastatic Therapeutic HER2-Negative Breast Cancer Ruxolitinib/placebo provided Page 3 of 17 September 1, 2015

BRE-258: WO29522 (pending 3rd Qtr) A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Phase III MPDL3280A (Anti-PD-L1 Antibody) in Combination with Nab-Paclitaxel Therapeutic Compared with Placebo with Nab-paclitaxel for Patients with Previously MPDL3280A/placebo provided Untreated Metastatic Triple-Negative Breast Cancer

METASTATIC, SECOND- OR THIRD-LINE, HER2- BRE-266: GO29689 (pending 4th Qtr) A Phase II, Open-Label, Randomized Study of GDC-0810 versus Fulvestrant Phase II in Postmenopausal Women with Advanced or Metastatic ER+/HER2- Breast Therapeutic Cancer Resistant to Aromatase Inhibitor Therapy GDC-0810 provided

METASTATIC, REFRACTORY, ER/PR POSITIVE BRE-242: INCB 18424-268 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Phase II Combination with Capecitabine in Subjects With Advanced or Metastatic Therapeutic HER2-Negative Breast Cancer Ruxolitinib/placebo provided

METASTATIC, REFRACTORY, HER2+ BRE-200 (Phase 1 open at BAM only) A Phase II Study with Lead-In Safety Cohort of Cabazitaxel plus Lapatinib as Phase II Therapy for HER2-Positive Metastatic Breast Cancer Patients with Therapeutic Intracranial Metastases Cabazitaxel/Lapatinib provided

BRE-240: 9785-CL-1121 Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Phase II Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Therapeutic Locally Advanced Breast Cancer Enzalutamide provided

BRE-249: MM-302-02-02-03 A Randomized, Multicenter, Open Label Study of MM-302 plus Phase II Trastuzumab vs. Chemotherapy of Physician’s Choice plus Trastuzumab in Therapeutic Anthracycline Naïve Patients with Locally Advanced/Metastatic HER2- MM-302 provided Positive Breast Cancer

Page 4 of 17 September 1, 2015

METASTATIC, REFRACTORY, TNBC BRE-231: CDX011-04 A Randomized Multicenter Phase II Study of CDX-011 (CR011-vcMMAE) in Phase II Patients with Metastatic, GPNMB Over-Expressing, Triple Negative Breast Therapeutic Cancer CDX-011 provided

BRE-242: INCB 18424-268 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Phase II Combination with Capecitabine in Subjects With Advanced or Metastatic Therapeutic HER2-Negative Breast Cancer Ruxolitinib/placebo provided

Colorectal/Rectal Clinical Trials METASTATIC, REFRACTORY GI-198: INCB 18424-267 A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Phase III Combination with Regorafenib in Subjects with Relapsed or Refractory Therapeutic Metastatic Colorectal Cancer Ruxolitinib/placebo provided

Esophageal/Gastric Clinical Trials FIRST-LINE GI-185: BO25114 A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination Therapeutic with Trastuzumab and Chemotherapy in Patients with HER2-Positive Pertuzumab/placebo, Trastuzumab Metastatic Gastroesophageal Junction and Gastric Cancer provided

GI-208: I4T-MC-JVCU A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Phase III Capecitabine and Cisplatin With or Without as First-line Therapeutic Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Ramucirumab/placebo provided Adenocarcinoma (RAINFALL)

Page 5 of 17 September 1, 2015

METASTATIC GI-202: C26002 (ON HOLD) A Phase 2 Trial of MLN0264 in Previously Treated Patients with Metastatic Phase II or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Therapeutic Junction Expressing Guanylyl cyclase (GCC) MLN0264 provided

METASTATIC, SECOND-LINE GI-201 A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line Phase II Treatment of Patients with Metastatic Gastroesophageal Cancer Therapeutic Nab-paclitaxel provided

Kidney Clinical Trials METASTATIC, FIRST-LINE GU-122: WO29637 (pending 3rd Qtr) A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Phase III Antibody) in Combination with Bevacizumab versus Sunitinib in Patients Therapeutic with Untreated Advanced Renal Cell Carcinoma. MPDL3280A and Bevacizumab provided

GU-127: CA209374 (pending 3rd Qtr) A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects with Phase 3b/4 Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During Therapeutic or After Received Prior Anti-Angiogenic Therapy CheckMate 374: Nivolumab provided CHECKpoint pathway and nivoluMAB Evaluation 374

GU-128: C31005 (pending) A Phase 2, Open-labe Study to Evaluate the Efficacy and Safety of Single- Phase II Agent MLN0128 and Combination of MLN0128+MLN1117 Compared with Therapeutic Everolimus in the Treatment of Adult Patients with Advanced Clear-Cell MLN0128 and MLN1117 provided Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Page 6 of 17 September 1, 2015

Lung – Non Small Cell Clinical Trials STAGE 1B-111A, EGFR+ LUN-305: D5164C0001 (pending) A Phase III, Double-Blind, Randomized, Placebo-Controlled Multi-centre, Phase III Study to Assess the Efficacy and Safety of AZD9291 versus Placebo, in Therapeutic Patients with Epidermal Growth Factor Receptor Mutation Positive Stage AZD9291/placebo provided IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumor Resection With or Without Adjuvant Chemotherapy (ADAURA)

LUN-308: GO29527 (pending 4th Qtr) A Phase III, Open label, Randomized Study to Investigator the Efficacy and Phase III Safety of MDPL3280A (Anti-PDL1 Antibody) Compared with Standard of Therapeutic Care Following Adjuvant Cisplatin-based Chemotherapy in PD-1 Selected provided Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

STAGE III; UNRESECTABLE LUN-282: D419C10001 A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, Phase III International Study of MEDI4736 as Sequential Therapy in Patients with Therapeutic Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who MEDI4736 Have Not Progressed Following Definitive, Platinum-Based, Concurrent Chemoradiation Therapy (PACIFIC)

STAGE IIIB/IV, FIRST-LINE LUN-263: ABI-007-NSCL-003 A Phase III, Randomized, Open-Label, Crossover, Multi-Center, Safety and Phase III Efficacy Study to Evaluate Nab-Paclitaxel (ABRAXANE) as Maintenance Therapeutic Treatment After Induction with Nab-Paclitaxel Plus Carboplatin in Subjects Nab-Paclitaxel provided with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

STAGE IIIB/IV, SECOND-LINE LUN-291: EMR100070-004 A Phase III open-label, multicenter trial of MSB0010718C versus docetaxel Phase III in subjects with PD-L1 positive non-small cell lung cancer that has Therapeutic progressed after a platinum-containing doublet MSB0010718C provided

Page 7 of 17 September 1, 2015

1ST-LINE METASTATIC LUN-288: I6A-MC-CBBE A Phase II Study of the Combination of LY3023414 and after Phase II First-Line Chemotherapy for Metastatic Squamous Non-Small Cell Therapeutic Carcinoma of the Lung LY3023414, Necitumumab provided

LUN-298: GO29437 (pending 4th Qtr) A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Phase III Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination Therapeutic with Carboplatin + Paclitaxel or MPDL3280A in Combination with MPDL3280A provided Carboplatin + Nab-Paclitaxel versus Carboplatin + Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

LUN-299: GO29537 (pending 4th Qtr) A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Phase III Efficacy and Safety of PDL3280A (Anti-PD-L1 Antibody) in Combination Therapeutic with Carboplatin-Nab-Paclitaxel for Chemotherapy-Naïve Patients with MPDL3280A provided Stage IV Non-Squamous Non-Small Cell Lung Cancer

RELAPSED/REFRACTORY LUN-214 Phase II Trial of Erlotinib and BMK120 in Patients with Advanced Non- Phase II Small-Cell Lung Cancer Previously Sensitive to Erlotinib Therapeutic BKM120 provided

LUN-264: PPHM 1202 (SECOND LINE ONLY) SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Phase III Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone as Therapeutic Second-Line Therapy in Patients with Stage IIIB/IV Non-Squamous Non Bavituximab provided Small-Cell Lung Cancer

LUN-270: D4191C00003 A Phase II, Non-comparative, Open label, Multi-centre, International Study Phase II of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Therapeutic Cell Lung Cancer who have Received at Least Two Prior Systemic MEDI4736 provided Treatment Regimens including One Platinum-based Chemotherapy Regimen (ATLANTIC)

Page 8 of 17 September 1, 2015

LUN-283: D4191C0004 A Phase III, Open label, Randomised, Multi-centre, International Study of Phase III MEDI4736 versus Standard of Care in Patients with Locally Advanced or Therapeutic Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received MEDI4736 provided at Least Two Prior Systemic Treatment Regimens Including One Platinum- based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)

LUN-284: I3Y-MC-JPBK A Randomized Phase 3 Study of LY2835219 versus Erlotinib in Patients with Phase III Stage IV NSCLC with a detectable KRAS mutation who have progressed Therapeutic after platinum-based chemotherapy LY2835219 provided

Lung – Small Cell Clinical Trials LUN-244: 59R5-003 A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Phase 1b/2 Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer Therapeutic also now known as PINNACLE OMP-59R5/placebo provided

METASTATIC, RELAPSED/REFRACTORY LUN-286: ALDOXORUBICIN-P2-SCLC-01 A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Phase 2b Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects Therapeutic with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Aldoxorubicin and topotecan required Refractory to Prior Chemotherapy

Neuroendocrine ADVANCED GI-195 Phase II Study of Carfilzomib for the Treatment of Patients with Advanced Phase II Neuroendocrine Cancers Therapeutic Carfilzomib provided

Page 9 of 17 September 1, 2015

Ovarian Clinical Trials SECOND-LINE, UNRESECTABLE GYN-52: PM1183-C-004-14 (pending) Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Phase III Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum- Therapeutic resistant Ovarian Cancer (CORAIL Trial) PM01183 provided

THIRD-LINE GYN-41: ET743-OVC-3006 A Randomized, Open-Label Study Comparing the Combination of YONDELIS Phase III and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Therapeutic Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Yondelis provided Tube

Pancreas Clinical Trials ADJUVANT GI-194: ABI-007-PANC-003 A Phase 3, Multicenter, Open-Label, Randomized Study of nab-Paclitaxel Phase III Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Therapeutic Subjects with Surgically Resected Pancreatic Adenocarcinoma Nab-Paclitaxel provided

METASTATIC; SECOND-LINE GI-199: INCB 18424-363 (ON HOLD) A Randomized, Double-Blinded Phase 3 Study of the JAK1/2 Inhibitor Phase III Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Therapeutic Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed Ruxolitinib/placebo provided or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)

GI-203: C26003 (ON HOLD) A Phase 2 Trial of MLN0264 in Previously Treated Patients with Advanced Phase II or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C Therapeutic (GCC) MLN0264 provided

Page 10 of 17 September 1, 2015

GI-204: INCB 18424-362 (pending 3rd Qtr) A Randomized, Double-Blind, Phase 3 Study of the JAK ½ Inhibitor, Phase III Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Therapeutic Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed Ruxolitinib/placebo provided or Are Intolerant to First-Line Chemotherapy (the JANUS 1 Study)

Prostate Clinical Trials PHASE 1, METASTATIC, RELAPSED/REFRACTORY GU-99: LOI GU 2012-01 Enzalutamide plus Everolimus in Men with Metastatic Castrate-Resistant Phase I Prostate Cancer and Previous Treatment with Docetaxel: A Phase I Study Therapeutic with a Maximum Tolerated Dose Expansion Cohort Everolimus, Enzalutamide provided

METASTATIC GU-115: I6A-MC-CBBD (pending 3rd Qtr) A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Phase II Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 Therapeutic in Men with Metastatic Castration Resistant Prostate Cancer LY3023414 provided

Soft Tissue Sarcoma ADVANCED/METASTATIC SARC-03: I5B-MC-JGDJ (pending 3rd Qtr) A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Therapeutic Doxorubicin plus versus Doxorubicin plus Placebo in Patients Phase III with Advanced or Metastatic Soft Tissue Sarcoma Olaratumab/placebo provided

Page 11 of 17 September 1, 2015

Urothelial LOCALLY ADVANCED/UNRESECTABLE/METASTATIC GU-120: I4T-MC-JVDC A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Phase III Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients Therapeutic with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Ramucirumab provided Who Progressed on or After Platinum-Based Therapy

Hematological Malignancies LYM-89: GS-US-339-0102 A Phase 2 Open Label, Study Evaluating the Efficacy , Safety, Tolerability, Phase II and Pharmacodynamics of GS-9973 in Patients with Relapsed or Refractory Therapeutic Hematologic Malignancies GS-9973

ACUTE MYELOID LEUKEMIA FIRST-LINE AML-24: MEI-009 (pending 3rd Qtr) A Phase III, Global, Double-Blinded, Placebo-Controlled, Multicenter, Phase III Randomized Study of Pracinostat in Combination with Azacitidine (AZA) in Therapeutic Patients ≥ 60 Years with Newly Diagnosis Acute Myeloid Leukemia (AML) Pracinostat/placebo provided

AML-25: CLT008-03 (pending) An Open-Label, Phase 2 Prospective, Randomized, Controlled Study of CLT- Phase II 008 Myeloid Progenitor Cells as a Supportive Care Measure During Therapeutic Induction Chemotherapy for Acute Myeloid Leukemia CLT-008 provided

AML-26: GS-US-339-1559 (pending) A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Phase Ib/II Combination with Chemotherapy in Subjects with Acute Myeloid Leukemia Therapeutic (AML) GS-9973 provided

Page 12 of 17 September 1, 2015

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FIRST-LINE CLL-34: PCYC-1130-CA A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Phase III Tyrosine Kinase Inhibitor Ibrutinib in Combination with Therapeutic versus Chlorambucil in Combination with Obinutuzumab in Subject’s with Ibrutinib, chlorambucil, and obinutuzumab Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic provided Lymphoma

RELAPSED/REFRACTORY CLL-30: IPI-145-07 A Phase 3 Study of IPI-145 versus in Patients with Relapsed Phase III or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Therapeutic Lymphoma IPI-145, Ofatumumab provided

CLL-31: IPI-145-12 A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Rollover Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI- Therapeutic 145-07 (CLL-30 Rollover Study) IPI-145, Ofatumumab provided

CLL-35: UTX-IB-301 A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Phase III in Combination with Ibrutinib Compared to Ibrutinib Alone, in Therapeutic Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia Ublituximab provided (CLL)

CHRONIC MYELOGENOUS LEUKEMIA (CML) SECOND-LINE CML-18: CA180-399 An Open Label, Randomized Phase IV Study of Dasatinib vs. Imatinib in the Phase IV Treatment of Subjects with Chronic Phase Chronic Myeloid Leukemia who Therapeutic Have not Optimally Responded to 3 Months of Therapy with 400 mg Dasatinib provided Imatinib

Page 13 of 17 September 1, 2015

DIFFUSE LARGE B-CELL LYMPHOMA LYM-82: GO27834 (phase I/KWD only) A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Phase Ib/II Safety and Activity of (DCDT2980S) in Combination Therapeutic With or (DCDS4501A) in Combination DCDS4501A provided With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination with Obinutuzumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

HODGKINS DISEASE FIRST-LINE LYM-84: C25003 A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Phase III Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma Therapeutic provided

RELAPSED/REFRACTORY LYM-105: INCB 40093-201 A Phase 2, Open-Label Study of the Safety and Efficacy of INCB040093 and Phase II INCB039110 in Subjects With Relapsed or Refractory Hodgkin Lymphoma Therapeutic INCB040093, INCB039110 provided

MULTIPLE MYELOMA MM-56: CFZ013 (phase 1 at KWD only) Phase 1b Study of Carfilzomib Administered Once Weekly in Combination Phase Ib with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma Therapeutic Carfilzomib provided

FIRST LINE E1A11 (ON HOLD) E1A11, Randomized Phase III Trial of Bortezomib, Lenalidomide and Phase III Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Therapeutic Dexamethasone (CRd) Followed by Limited or Indefinite Duration Carfilzomib provided Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Principal

Page 14 of 17 September 1, 2015

RELAPSED/REFRACTORY MM-42: LOI BMT2012-002 (ON HOLD) A Phase I/II study evaluating maintenance MLN9708 following an Phase I/II allogeneic transplant for multiple myeloma Therapeutic MLN9708 provided

MM-50 Phase II Trial of LDE225 followed by Bortezomib in Patients with Relapsed Phase II or Relapsed/Refractory Multiple Myeloma with a Dose-Finding Lead-In Therapeutic LDE225 provided

SMOULDERING MM-60: 54767414SMM2001 (pending 3rd A Randomized Phase 2 Trial to Evaluate Three Dose Qtr) Schedules in Smoldering Multiple Myeloma Phase II Therapeutic Daratumumab provided

MYELODYSPLASTIC SYNDROME BMT CTN 1102 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Observational Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or No drug provided Best Supportive Care in Patients Aged 50-75 w/Intermediate-2 & High Risk Myelodysplastic Syndrome

MDS-16: TL32711-RAN-0094-PTL A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Phase II Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Therapeutic Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Birinapant provided Myelomonocytic Leukemia

MYELOPROLIFERATIVE NEOPLASMS MPN-06: PAC326 A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Phase III Available Therapy in Patients with Thrombocytopenia and Primary Therapeutic Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Pacritinib provided Thrombocythemia Myelofibrosis

Page 15 of 17 September 1, 2015

MPN-07: 63935937MYF2001 (pending) A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Phase II Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or Therapeutic High-Risk Myelofibrosis (MF) Relapsed/Refractory of Janus Kinase (JAK) Imetelstat provided Inhibitor

MPN-08: WO29806 (pending 4th Qtr) A Phase IB/II, Randomized, Double-Blind, Placebo-Controlled Study to Phase IB/II Evaluate the Efficacy and Safety of Vismodegib in Combination with Therapeutic Ruxolitinib Versus Placebo and Ruxolitinib in Intermediate to High Risk Vismodegib/placebo & Ruxolitinib provided Myelofibrosis

NON-HODGKIN’S LYMPHOMA-FOLLICULAR FIRST-LINE LYM-99: GS-US-313-1414 (pending 4th Qtr) A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib Phase II in Combination with Rituximab for Previously Untreated Indolent Non- Therapeutic Hodgkin Lymphoma Idelalisib provided

LYM-104: GO27878 (pending 3rd Qtr) A Phase IB/II, Open-Label Study Evaluating the Safety and Phase IB/II Pharmacokinetics of GDC-0199 (ABT-199) in Combination with Rituximab Therapeutic or Obinutuzumab plus Cyclophosphamide, Doxorubicin, Vincristine, and GDC-0199 provided Prednisone (CHOP) in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL) and DLBCL

SGN35-014 (KWD only) A Phase IB/II, Open-Label Study Evaluating the Safety and Phase III Pharmacokinetics of GDC-0199 (ABT-199) in Combination with Rituximab Therapeutic or Obinutuzumab plus Cyclophosphamide, Doxorubicin, Vincristine, and Brentuximab vedotin provided Prednisone (CHOP) in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL) and DLBCL

RELAPSED/REFRACTORY LYM-106: CC-5013-NHL-007 (pending 3rd Qtr) A Phase 3, Double-Blind Randomized Study to Compare the Efficacy and Phase III Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Therapeutic Placebo in Subjects with Relapsed/Refractory Indolent Lymphoma (The Lenalidomide/placebo provided “AUGMENT” Trial)

Page 16 of 17 September 1, 2015

TRANSPLANT BMT-10: INCB 039110-108 (pending 4th qtr) A Randomized, Parallel-Cohort Phase I Study of INCB039110 in Phase I Combination with Corticosteriods for the Treatment of Grade II-IV Acute Therapeutic Graft-Versus-Host Disease INCB039110 provided

BMT CTN 07LT (KWD only) Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy Phase III for Patients on BMT CTN 0702 Protocol Therapeutic Lenalidomide

BMT CTN 1101 (KWD only) A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Phase III Conditioning and Transplantation of Double Unrelated Umbilical Cord Therapeutic Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) No drug provided for Patients with Hematologic Malignancies

BMT CTN 1205 (KWD only) Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Phase II Transplantation Clinical Trials Therapeutic No drug provided

CIBMTR 10-CBA (KWD only) A Multicenter Access and Distribution Protocol for Unlicensed Observational Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and No drug provided Adult Patients with Hematologic Malignancies and Other Indications

CMX001-301 (KWD only) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Multicenter, Phase 3 Study of the Safety, Tolerability and Efficacy of Therapeutic CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV- CMX-001 provided seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

NMDP Research Repository (KWD only) Allogenic Hematopoietic Stem Cell Transplantation and Marrow Toxic Observational Injuries/Hematopietic Cell Transplantation, Other Cellular Therapies and No drug provided Marrow Toxic Injuries

Page 17 of 17 September 1, 2015